TY  - JOUR
AU  - Sarink, Danja
AU  - Schock, Helena
AU  - Johnson, Theron Scot
AU  - Chang-Claude, Jenny
AU  - Overvad, Kim
AU  - Olsen, Anja
AU  - Tjønneland, Anne
AU  - Arveux, Patrick
AU  - Fournier, Agnès
AU  - Kvaskoff, Marina
AU  - Boeing, Heiner
AU  - Karakatsani, Anna
AU  - Trichopoulou, Antonia
AU  - La Vecchia, Carlo
AU  - Masala, Giovanna
AU  - Agnoli, Claudia
AU  - Panico, Salvatore
AU  - Tumino, Rosario
AU  - Sacerdote, Carlotta
AU  - van Gils, Carla H
AU  - Peeters, Petra H M
AU  - Weiderpass, Elisabete
AU  - Agudo, Antonio
AU  - Rodríguez-Barranco, Miguel
AU  - Huerta, José María
AU  - Ardanaz, Eva
AU  - Gil, Leire
AU  - Kaw, Kay Tee
AU  - Schmidt, Julie A
AU  - Dossus, Laure
AU  - His, Mathilde
AU  - Aune, Dagfinn
AU  - Riboli, Elio
AU  - Kaaks, Rudolf
AU  - Turzanski-Fortner, Renée
TI  - Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
JO  - BMC cancer
VL  - 18
IS  - 1
SN  - 1471-2407
CY  - Heidelberg
PB  - Springer
M1  - DKFZ-2018-01855
SP  - 1010
PY  - 2018
AB  - Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to provide the first data on pre-diagnosis concentrations of sRANKL and OPG and risk of breast cancer-specific and overall mortality after a breast cancer diagnosis.Two thousand six pre- and postmenopausal women with incident invasive breast cancer (1620 (81
LB  - PUB:(DE-HGF)16
C6  - pmid:30348163
C2  - pmc:PMC6196438
DO  - DOI:10.1186/s12885-018-4887-3
UR  - https://inrepo02.dkfz.de/record/141336
ER  -